Notably, the clinical efficacy of IL-1 inhibition (anakinra) and IL-6 inhibition (tocilizumab or sarilumab) was studied in COVID-19 patients with respiratory insufficiency and hyperinflammation. The gene discussed is IL6; the disease is COVID-19.